Frequência de transtorno de humor e impacto na qualidade de vida dos pacientes portadores de HTLV-1 com paraparesia espástica tropical

Gascón, Maria Rita Polo.
São Paulo; s.n; 2010. 121 p. tab.
Tese em Português | LILACS, SES-SP, SESSP-CTDPROD, SES-SP, SESSP-TESESESSP, SES-SP | ID: biblio-1073974

Documentos relacionados

  1. Long-term safety and efficacy of mogamulizumab (anti-CCR4) for treating virus-associated myelopathy.
  2. Performance of the National Institute of Infectious Diseases disability scale in HTLV-1-associated myelopathy/tropical spastic paraparesis.
  3. CD49d Is Upregulated in Circulating T Lymphocytes from HTLV-1-Infected Patients.
  4. Spirituality as Strategies for Coping With Tropical Spastic Paraparesis: Results of Focus Group.
  5. Anti-Human T-Cell Leukemia Virus Type 1 (HTLV-1) Antibody Assays in Cerebrospinal Fluid for the Diagnosis of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.
  6. Patient research priority setting partnership in human T-cell lymphotropic virus type I.
  7. Identification of dysregulated pathways underlying HTLV-1-associated myelopathy/tropical spastic paraparesis through co-expression network analysis.
  8. Pain, psychoaffective symptoms, and quality of life in human T cell lymphotropic virus type 1 (HTLV-1): a cross-sectional study.
  9. HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors.
  10. Mogamulizumab for Treatment of Human T-lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Single-Center US-based Series.